Citigroup Maintains Buy on AbbVie, Raises Price Target to $215
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Andrew Baum maintains a Buy rating on AbbVie and raises the price target from $170 to $215.
October 25, 2024 | 6:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Andrew Baum has maintained a Buy rating on AbbVie and increased the price target from $170 to $215, indicating a positive outlook for the stock.
The increase in price target from $170 to $215 by Citigroup suggests a strong positive outlook for AbbVie's stock. Maintaining a Buy rating further supports the expectation of upward price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100